Johnson & Johnson (NYSE:JNJ) Shares Acquired by ZWJ Investment Counsel Inc.

ZWJ Investment Counsel Inc. raised its position in Johnson & Johnson (NYSE:JNJ) by 0.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 208,857 shares of the company’s stock after purchasing an additional 1,760 shares during the quarter. ZWJ Investment Counsel Inc.’s holdings in Johnson & Johnson were worth $30,205,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in JNJ. Wescott Financial Advisory Group LLC grew its stake in shares of Johnson & Johnson by 50.5% in the second quarter. Wescott Financial Advisory Group LLC now owns 16,637 shares of the company’s stock worth $2,432,000 after purchasing an additional 5,581 shares in the last quarter. Zurich Insurance Group Ltd FI raised its stake in shares of Johnson & Johnson by 366.6% during the second quarter. Zurich Insurance Group Ltd FI now owns 145,105 shares of the company’s stock valued at $21,209,000 after purchasing an additional 114,005 shares in the last quarter. Fred Alger Management LLC grew its position in Johnson & Johnson by 6.1% in the 2nd quarter. Fred Alger Management LLC now owns 42,968 shares of the company’s stock valued at $6,280,000 after buying an additional 2,488 shares in the last quarter. Toronto Dominion Bank increased its stake in Johnson & Johnson by 13.0% during the 2nd quarter. Toronto Dominion Bank now owns 1,197,314 shares of the company’s stock valued at $174,999,000 after buying an additional 137,292 shares during the period. Finally, Trinity Legacy Partners LLC raised its position in shares of Johnson & Johnson by 5.7% during the 2nd quarter. Trinity Legacy Partners LLC now owns 31,616 shares of the company’s stock worth $4,621,000 after buying an additional 1,699 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ opened at $145.39 on Thursday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $350.04 billion, a P/E ratio of 21.04, a PEG ratio of 2.50 and a beta of 0.51. The stock has a fifty day moving average of $148.26 and a 200-day moving average of $156.12.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.29 EPS. Equities analysts forecast that Johnson & Johnson will post 9.95 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Wells Fargo & Company lifted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, January 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $173.27.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.